Sign in

You're signed outSign in or to get full access.

Lauren

former analyst in consumer & retail investment banking at Jefferies Financial Group Inc.

Lauren Beauchamp is a former analyst in consumer & retail investment banking at Jefferies Financial Group Inc., where she specialized in company valuations and sector strategy for numerous consumer and retail companies. Her work included supporting deal execution and strategic advisory across brands in the consumer space, leveraging her economics and finance background to deliver insightful analyses and recommendations. Lauren began her finance career at PwC in valuations and strategy consulting before joining Jefferies as an analyst, and later advanced to her current role as Vice President at Norwest Venture Partners in growth equity. She earned a Master of Science in Economics and a Bachelor of Science in Business Administration (Finance concentration) from California Polytechnic State University.

Lauren's questions to NEOGENOMICS (NEO) leadership

Question · Q3 2025

Lauren inquired about the expected timeline for rebounding growth in the pharma and non-clinical segments (likely 2027), the evolving adoption of RaDaR in pharma partnerships versus the clinical setting, and the specific investments and initiatives reinforcing NeoGenomics' "partner of choice" position for community oncologists.

Answer

COO Warren Stone confirmed expectations for MRD revenue in the pharma space in 2026, which could offset other headwinds. He detailed "partner of choice" initiatives, including a relevant portfolio (PanTracer family, c-MET, claudin18, comprehensive MRD suite), bi-directional interfaces, and a best-in-class customer experience to remove friction for community oncology practices. CFO Jeff Sherman noted that historically, RaDaR Pharma revenue reached $6M-$7M annually after a couple of years, indicating a ramp-up for re-engagement.

Ask follow-up questions

Fintool

Fintool can predict NEOGENOMICS logo NEO's earnings beat/miss a week before the call

Question · Q3 2025

Lauren inquired about how Radar adoption is evolving in pharma partnerships versus the clinical setting, particularly in the context of rebounding growth in the pharma and non-clinical segments. She also asked about specific investments or initiatives reinforcing NeoGenomics' position as a 'partner of choice' for community oncologists.

Answer

COO Warren Stone stated that MRD revenue is expected from the pharma space in 2026, which will help address headwinds. He explained that the 'partner of choice' position is reinforced by a relevant portfolio (PanTracer, CMET, Claudin 18, and a comprehensive MRD suite), bi-directional interfaces, and a focus on client customer experience to remove friction for practices. CFO Jeff Sherman added that historically, Radar Pharma generated $6-7 million annually after a couple of years, indicating a ramp-up period for re-engagement in the market.

Ask follow-up questions

Fintool

Fintool can write a report on NEOGENOMICS logo NEO's next earnings in your company's style and formatting

Lauren's questions to 10x Genomics (TXG) leadership

Question · Q2 2025

Lauren asked about the discounting on Chromium instruments, questioning if this strategy would continue and how pricing is expected to evolve.

Answer

CEO Serge Saxonov confirmed that the discounting is a direct response to the challenging CapEx environment, allowing them to work creatively with customers who face new spending restrictions. He expects this accretive strategy, which often includes reagent commitments, to continue as long as the current market conditions persist.

Ask follow-up questions

Fintool

Fintool can predict 10x Genomics logo TXG's earnings beat/miss a week before the call